Cargando…

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms

Medullary thyroid carcinoma is a rare malignant tumor originating in parafollicular C cells. It accounts for 5 to 8% of all thyroid cancers. MTC develops in either sporadic (75%) or hereditary form (25%). Genetic and molecular studies have demonstrated the involvement of the RET proto-oncogene in he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceolin, Lucieli, Siqueira, Débora R., Romitti, Mírian, Ferreira, Carla V., Maia, Ana Luiza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269683/ https://www.ncbi.nlm.nih.gov/pubmed/22312249 http://dx.doi.org/10.3390/ijms13010221

Ejemplares similares

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Advanced medullary thyroid cancer: pathophysiology and management
por: Ferreira, Carla Vaz, et al.
Publicado: (2013)

Role of VEGF-A and Its Receptors in Sporadic and MEN2-Associated Pheochromocytoma
por: Ferreira, Carla Vaz, et al.
Publicado: (2014)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
por: Sahakian, Nicolas, et al.
Publicado: (2023)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies
por: Colombo, Carla, et al.
Publicado: (2015)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Somatic Mutations in the RET Protooncogene in Japanese and Chinese Sporadic Medullary Thyroid Carcinomas
por: Shan, Liang, et al.
Publicado: (1998)

A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma
por: Mohammadi, Masoumeh, et al.
Publicado: (2017)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

Novel Point Mutations and Allele Loss at the RET Locus in Sporadic Medullary Thyroid Carcinomas
por: Uchino, Shinya, et al.
Publicado: (1998)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
por: Bim, Larissa V., et al.
Publicado: (2019)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

Large‐scale Analysis of Mutations in RET Exon 16 in Sporadic Medullary Thyroid Carcinomas in Japan
por: Takano, Torn, et al.
Publicado: (2001)

Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity
por: Alqahtani, Tariq, et al.
Publicado: (2021)

MON-562 Retrospective Analysis of Medullary Thyroid Carcinoma: Comparison between Individuals with and without RET Germline Mutation
por: Costa, Cláudia, et al.
Publicado: (2019)

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
por: Prazeres, Hugo, et al.
Publicado: (2011)

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency
por: Milićević, Sara, et al.
Publicado: (2021)

A Case of Medullary Thyroid Carcinoma with de novo V804M RET Germline Mutation
por: Choi, Young Sik, et al.
Publicado: (2013)

Haplotype Frequency of G691S/S904S in the RET Proto-Onco-gene in Patients with Medullary Thyroid Carcinoma
por: SHEIKHOLESLAMI, Sara, et al.
Publicado: (2014)

RET gene mutations spectrum in patients with medullary thyroid carcinoma (MTC) from Great Poland region
por: Kaczmarek-Ryś, Marta, et al.
Publicado: (2015)

Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study
por: Mathiesen, Jes Sloth, et al.
Publicado: (2019)

Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2017)

CRISPR/Cas9 RET Gene Knockout in Medullary Thyroid Carcinoma Cell-lines: Optimization and Validation
por: Zarif-Yeganeh, Marjan, et al.
Publicado: (2022)

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
por: Prazeres, Hugo, et al.
Publicado: (2016)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma
por: Hedayati, Mehdi, et al.
Publicado: (2011)

Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility
por: Toledo, Rodrigo A, et al.
Publicado: (2015)

Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation
por: Ehyaei, Samira, et al.
Publicado: (2017)

SAT-566 Cofilin Is a Mediator of RET-Promoted Medullary Thyroid Carcinoma Cell Migration, Invasion and Proliferation
por: Peverelli, Erika, et al.
Publicado: (2019)

LBODP099 A Young Patient With Undifferentiated And Advanced Medullary Thyroid Carcinoma With Negative RET - CASE REPORT
por: Fraga, Lais Oliveira Teles, et al.
Publicado: (2022)

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes
por: Alqahtani, Tariq, et al.
Publicado: (2023)

RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report
por: Neocleous, Vassos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d3qv2faku0k005ok4jcuoeb8nq